Product Name
SLC19A3, siRNA
Full Product Name
SLC19A3 siRNA (Human)
Product Synonym Names
Thiamine transporter 2; ThTr-2; ThTr2; Solute carrier family 19 member 3
Product Gene Name
SLC19A3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9BZV2
Specificity
SLC19A3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SLC19A3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of SLC19A3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
SLC19A3 sirna
siRNA to inhibit SLC19A3 expression using RNA interference
Applications Tested/Suitable for SLC19A3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for SLC19A3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_079519.1
[Other Products]
NCBI GenBank Nucleotide #
NM_025243.3
[Other Products]
UniProt Primary Accession #
Q9BZV2
[Other Products]
UniProt Related Accession #
Q9BZV2[Other Products]
Molecular Weight
55,665 Da
NCBI Official Full Name
thiamine transporter 2
NCBI Official Synonym Full Names
solute carrier family 19 (thiamine transporter), member 3
NCBI Official Symbol
SLC19A3??[Similar Products]
NCBI Official Synonym Symbols
BBGD; THMD2; THTR2
??[Similar Products]
NCBI Protein Information
thiamine transporter 2
UniProt Protein Name
Thiamine transporter 2
UniProt Synonym Protein Names
Solute carrier family 19 member 3
Protein Family
Thiamine transporter
UniProt Gene Name
SLC19A3??[Similar Products]
UniProt Synonym Gene Names
ThTr-2; ThTr2??[Similar Products]
UniProt Entry Name
S19A3_HUMAN
NCBI Summary for SLC19A3
This gene encodes a ubiquitously expressed transmembrane thiamine transporter that lacks folate transport activity. Mutations in this gene cause biotin-responsive basal ganglia disease (BBGD); a recessive disorder manifested in childhood that progresses to chronic encephalopathy, dystonia, quadriparesis, and death if untreated. Patients with BBGD have bilateral necrosis in the head of the caudate nucleus and in the putamen. Administration of high doses of biotin in the early progression of the disorder eliminates pathological symptoms while delayed treatment results in residual paraparesis, mild mental retardation, or dystonia. Administration of thiamine is ineffective in the treatment of this disorder. Experiments have failed to show that this protein can transport biotin. Mutations in this gene also cause a Wernicke's-like encephalopathy.[provided by RefSeq, Jan 2010]
UniProt Comments for SLC19A3
SLC19A3: Mediates high affinity thiamine uptake, propably via a proton anti-port mechanism. Has no folate transport activity. Defects in SLC19A3 are the cause of biotin-responsive basal ganglia disease (BBGD). BBGD is a recessive disorder with childhood onset that presents as a subacute encephalopathy, with confusion, dysarthria, and dysphagia, and that progresses to severe rigidity, dystonia, quadriparesis and death if not treated. Belongs to the reduced folate carrier (RFC) transporter (TC 2.A.48) family.
Protein type: Transporter, SLC family; Transporter; Membrane protein, multi-pass; Membrane protein, integral
Chromosomal Location of Human Ortholog: 2q37
Cellular Component: integral to membrane; plasma membrane
Molecular Function: thiamin uptake transmembrane transporter activity
Biological Process: vitamin metabolic process; thiamin and derivative metabolic process; water-soluble vitamin metabolic process
Disease: Thiamine Metabolism Dysfunction Syndrome 2 (biotin- Or Thiamine-responsive Type)
Research Articles on SLC19A3
1. Genetic variation in the SLC19A3 thiamine transporter at 2:228563818T/C may make a modest contribution towards the genetic susceptibility to alcohol dependence syndrome.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
